Improving characterization of monoclonal antibodies: Making a better biotherapeutic

Characterization of therapeutic proteins remains labor-intensive and time consuming due to their often complex and heterogeneous structure. This has led to a concerted effort within the biotechnology and

 biopharmaceutical industry to address these bottlenecks as a means to boost the development of more biotherapeutics. Studies in this vein, such as testing the effect of various cell culture conditions on posttranslational modifications or monitoring the purification process of recombinant proteins, produce large numbers of samples that can easily exceed the capacity of modern analytical laboratories. High throughput analytical platforms with high precision, automation, and ease-of-use are therefore in great demand. To this end, the use of microfluidic analytical platforms such as microchip capillary electrophoresis (CE) have greatly increased the efficiency and reproducibility needed for analyzing proteins intended for therapeutic use. In this webinar, our expert panelists will discuss posttranslational modifications and quality assessment of biotherapeutic proteins for biopharmaceutical development using microfluidic-CE characterization
During the webinar, viewers will
  • Gain a deeper understanding of the factors important in biotherapeutic protein production and characterization
  • Learn the fundamentals of microfluidics-based capillary electrophoresis
  • Hear how microchip-CE can speed protein analysis, particularly in the drug development pipeline
  • Have their questions answered live by the panelists!

Speaker Bios

Niomi Peckham, M.S.

Alexion Pharmaceuticals
Cheshire, Connecticut
Ms. Peckham has been with Alexion Pharmaceuticals since 2003 and is presently a scientist in their analytical sciences division, where she develops and validates methods for protein analysis as well as researching and evaluating new methodologies for use in the lab. Prior to this position, Ms. Peckham worked at Pfizer and Enzo Diagnostics. Her training was at the University of Connecticut for her undergraduate degree in biology/biotechnology, and the State University of New York for her Master’s in molecular and cellular biology

Friederike Winkhaus, Ph.D.

Roche Diagnostics GmbH
Munich, Germany
Dr. Winkhaus completed her Ph.D. in biochemistry (on the regulation of HCN2-Pacemaker channels) at the Center of Advanced European Studies and Research in Bonn, Germany, after which she undertook her postdoctoral research training at the Nestlé Research Center in Lausanne, Switzerland. Her work at Nestlé focused on the identification and characterization of feline receptors as palatability drivers. Since February 2014, she has been working in the Analytical Development Department of Roche Diagnostics GmbH in Penzberg, Germany. In this position, she is involved in the development of new analytical technologies with a focus on microfluidic technologies, including microchip capillary electrophoresis

Moderator: Sean Sanders, Ph.D.

Washington, DC
Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Editor for Custom Publishing for the journal Science and Program Director for Outreach
Share on Google Plus
    Blogger Comment
    Facebook Comment